注射用磷霉素钠临床应用回顾性真实世界研究

注册号:

Registration number:

ChiCTR1800015976 

最近更新日期:

Date of Last Refreshed on:

2025-05-06 10:49:35 

注册时间:

Date of Registration:

2018-05-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

注射用磷霉素钠临床应用回顾性真实世界研究

Public title:

A retrospective real-world study of the clinical application of fosfomycin sodium for injection

注册题目简写:

English Acronym:

研究课题的正式科学名称:

注射用磷霉素钠临床应用回顾性真实世界研究

Scientific title:

A retrospective real-world study of the clinical application of fosfomycin sodium for injection

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

江苏法迈生医学科技有限公司 

研究负责人:

杨帆 

Applicant:

Jiangsu Maimaisheng Medical Technology Co., Ltd. 

Study leader:

Yang Fan 

申请注册联系人电话:

Applicant telephone:

+86 25 5762 8226

研究负责人电话:

Study leader's
telephone:

+86 139 1634 6661

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

vip@famousmed.net

研究负责人电子邮件:

Study leader's E-mail:

961678602@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市鼓楼区汉中路282号

研究负责人通讯地址:

上海市静安区乌鲁木齐中路12号

Applicant address:

282 Hanzhong Road, Gulou District, Nanjing, Jiangsu, China

Study leader's address:

12 Urumqi Middle Road, Jing'an District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏法迈生医学科技有限公司

Applicant's institution:

Jiangsu Maimaisheng Medical Technology Co., Ltd.

研究负责人所在单位:

复旦大学华山医院

Affiliation of the Leader:

Fudan University Huashan Hospital Research

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ChiECRCT-20180054

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

中国注册临床试验伦理审查委员会

Name of the ethic committee:

China Ethics Committee of Registering Clinical Trials

伦理委员会批准日期:

Date of approved by ethic committee:

2018-04-30 00:00:00

伦理委员会联系人:

米娜

Contact Name of the ethic committee:

Mina

伦理委员会联系地址:

中国香港特别行政区九龙塘浸会大学道中国临床试验注册中心香港中心

Contact Address of the ethic committee:

Chinese Clinical Trial Registry Hong Kong Center, Hong Kong Baptist University Road, Hong Kong SAR, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学华山医院

Primary sponsor:

Fudan University Huashan Hospital Research

研究实施负责(组长)单位地址:

上海市静安区乌鲁木齐中路12号

Primary sponsor's address:

12 Urumqi Middle Road, Jing'an District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国研究型医院协会

具体地址:

北京市海淀区永定路24号

Institution
hospital:

China Research Hospital Association

Address:

24 Yongding Road, Haidian District, Beijing

经费或物资来源:

申办方资助

Source(s) of funding:

Sponsor funding

研究疾病:

感染  

Target disease:

infection

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

1.探索注射用磷霉素钠防治感染及感染相关疾病的处方科室、感染部位; 2.探索注射用磷霉素钠治疗耐药菌感染的病原菌及细菌清除情况; 3.探索不同用法用量注射用磷霉素钠临床使用的安全性和有效性; 4.探索注射用磷霉素钠与其他抗菌药物联合用药方案。  

Objectives of Study:

1.Exploring prescription and infection sites for the prevention and treatment of infection-related diseases by injection of fosfomycin sodium; 2.Exploring the use of fosfomycin sodium for the treatment of drug-resistant bacterial infections and bacterial eradication; 3.Exploring the safety and effectiveness of clinical use of fosfomycin sodium for different usage and dosage; 4.Explore the combination of fosfomycin sodium for injection and other antimicrobial agents.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

Exclusion criteria:

None

研究实施时间:

Study execute time:

From 2018-01-03 00:00:00 To 2018-10-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-05-03 00:00:00 To 2018-10-03 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

1000

Group:

Case series

Sample size:

干预措施:

N/A

干预措施代码:

Intervention:

N/A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院 

单位级别:

三甲 

Institution
hospital:

Huashan Hospital Affiliated to Fudan University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

临床疗效

指标类型:

主要指标

Outcome:

Clinical efficacy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

暂停或中断

Suspending

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不涉及随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Does not involve random

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not share raw data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本试验数据上传至医路EDC系统中

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The test data is uploaded to the medical road EDC system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2018-05-03 21:25:26